Journey Medical Reports 23% Revenue Growth in Q2 2026, Driven by Emrosi Momentum in Rosacea
核心洞察
Journey Medical Corporation reported total revenues of $18.5 million for the second quarter of 2026, a 23% increase from $15.0 million in the prior-year quarter.
Emrosi (搜索) generated $8.1 million in revenue during the quarter, with total prescriptions rising to approximately 36,000, up from 30,000 in Q1 2026 and 27,000 in Q4 2025.
GAAP net loss narrowed to $0.3 million, or $(0.01) per share, compared to a net loss of $3.8 million, or $(0.16) per share, in the second quarter of 2025.
Journey Medical Corporation (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on FDA-approved prescription products for dermatological conditions, reported total revenues of $18.5 million for the second quarter ended June 30, 2026, representing 23% growth from $15.0 million in the prior-year quarter. The increase was driven primarily by continued commercial demand momentum for Emrosi (搜索), the company's oral treatment for rosacea (搜索), which generated revenues of $8.1 million during the quarter.
Claude Maraoui, Journey Medical's Co-Founder, President and Chief Executive Officer, said, "We delivered solid performance in the second quarter, highlighted by 23% total net revenue growth, year over year, and continued progress toward profitability, driven by revenue growth and ongoing disciplined investment in our dermatology commercial infrastructure. Momentum behind Emrosi (搜索) remains strong, with sales of the product up significantly compared to both the prior-year period and the first quarter of this year."
Emrosi Commercial Traction
Emrosi (搜索) total prescriptions (TRx) reached approximately 36,000 for the second quarter of 2026, compared to approximately 30,000 for the first quarter of 2026 and 27,000 for the fourth quarter of 2025, reflecting sequential growth in prescription demand. Maraoui noted that "prescription demand and payer coverage for Emrosi are increasing as we establish the product as the best-in-class oral treatment for patients suffering from rosacea (搜索)."
Financial Performance
The company's gross margin was 67% for the second quarter of 2026, consistent with the prior-year quarter. Selling, general and administrative expenses were $10.9 million for the quarter, a decrease of $1.0 million from the second quarter of 2025, primarily due to a reduction in launch-related spending for Emrosi (搜索) compared to the prior-year period.
GAAP net loss narrowed to $0.3 million, or $(0.01) per share basic and diluted, for the second quarter of 2026, compared to a net loss of $3.8 million, or $(0.16) per share basic and diluted, for the second quarter of 2025. The company's non-GAAP results reflected positive EBITDA and Adjusted EBITDA for both the three- and six-month periods ended June 30, 2026, with non-GAAP Adjusted EBITDA of $2.9 million for the second quarter of 2026.
Balance Sheet and Outlook
At June 30, 2026, the company had $25.6 million in cash and cash equivalents, compared to $24.1 million at December 31, 2025. Maraoui stated, "With this progress and over $25 million in cash, we believe that we are well-positioned to execute on our strategy and deliver strong financial performance going forward."
Journey Medical, headquartered in Scottsdale, Arizona and founded by Fortress Biotech, Inc. (Nasdaq: FBIO), currently markets nine branded FDA-approved prescription drugs for common skin conditions. The company conducted a conference call and audio webcast on August 12, 2026, at 4:30 p.m. ET to discuss the results.